Pipeline Overview

Transforming Patient Outcomes In Chronic Diseases

ProterixBio is developing disease management platforms to improve patient outcomes, starting with pulmonary diseases. As a key part of these programs, ProterixBio will provide actionable biological measurements in order to improve patient assessment and enhance treatment decisions, solving critical unmet needs.

Our initial focus is COPD (chronic obstructive pulmonary disease), a progressive disease which causes reduced air flow in the lungs, leading to significant morbidity and mortality. The ultimate goal is to reduce the frequency and severity of exacerbations, slow progression, lower morbidity and mortality, and lower the overall cost of the disease.

ProterixBio is working with world class advisors to ensure the development of clinically useful tests which have a clear and compelling effect on patient outcomes. Our proprietary ViBE platform and AMMP assays enable efficient test development through the precise and reproducible analysis of proteins in blood, sputum and other sample types.

 

Enhancing Treatment Decisions To Improve Outcomes

 

Bioclinical Data and Analytics

Novel High-Value Tests

Novel High-Value Tests

Patient Monitoring & Engagement

Patient Monitoring & Engagement

Enhanced Decisions

Actionable Results

Better Outcomes

Slower
Progression

Lower
Morbidity

Lower
Mortality

Lower
Costs

Have interest in partnering with us?: